Infectivology and Clinical Trials Research Department, Children's Hospital Bambino Gesù, Rome, Italy.
VisMederi S.r.l., Siena, Italy.
Front Immunol. 2018 Oct 17;9:2374. doi: 10.3389/fimmu.2018.02374. eCollection 2018.
Regulatory T (Treg) cells represent a subpopulation of suppressor CD4 T cells critically involved in the establishment of peripheral tolerance through the inhibition of effector T (Teff) cells and the suppression of the immune-mediated tissue destruction toward self-antigens. Treg generation, their suppressive properties and also Treg-Teff cell interactions could be modulated at least in part by programmed cell death-1 (PD-1) expression on their surface and through binding between PD-1 and programmed cell death ligand-1 (PD-L1). Defects involving PD-1 and Tregs can lead to the development of pathological conditions, including autoimmune disorders or promote cancer progression by favoring tumor evasion from the host immune response. At the same time, PD-1 and Tregs could represent attractive targets for treatment, as demonstrated by the therapeutic blockade of PD-L1 applied for the management of different cancer conditions in humans. In the present Review, we focus specifically the role of PD-1/PD-L1 on Treg development and activity.
调节性 T(Treg)细胞是抑制性 CD4 T 细胞的一个亚群,通过抑制效应 T(Teff)细胞和抑制针对自身抗原的免疫介导的组织破坏,在建立外周耐受方面发挥着关键作用。Treg 的产生、其抑制特性以及 Treg-Teff 细胞的相互作用至少部分可以通过其表面表达的程序性细胞死亡-1(PD-1)和 PD-1 与程序性细胞死亡配体-1(PD-L1)之间的结合来调节。涉及 PD-1 和 Tregs 的缺陷可导致病理状况的发展,包括自身免疫性疾病,或通过促进肿瘤逃避宿主免疫反应而促进癌症进展。同时,PD-1 和 Tregs 可能是治疗的有吸引力的靶点,如通过在人类中应用 PD-L1 的治疗性阻断来治疗不同的癌症状况所证明的那样。在本综述中,我们特别关注 PD-1/PD-L1 对 Treg 发育和活性的作用。